Pipeline

Transposon’s robust pipeline includes novel nucleoside inhibitors of LINE-1 reverse transcriptase with TPN-101 in late-stage development for multiple indications and follow-on candidates in preclinical development, as well as Protein Kinase R inhibitors (PKRi) to target pathways activated by LINE-1 and implicated in cognitive impairment.

Transposon Pipeline

Asset	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
TPN-101	Progressive Supranuclear Palsy (PSP)					In planning
TPN-101	Amyotrophic Lateral Sclerosis (ALS) / Frontotemporal Dementia (FTD)					In planning
TPN-101	Aicardi-Goutières Syndrome (AGS)					Ongoing
TPN-101	Alzheimer's Disease & Others				In planning

Novel NRTIs	To be determined

Novel PKRi	Disorders of cognition